Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Extracorporeal Shock Wave Therapy in Patients With Lipedema

NCT: NCT07683559 · NOT_YET_RECRUITING

NCT IDNCT07683559
StatusNOT_YET_RECRUITING
Start Date2026-07-01
Completion2027-01-01
SponsorAtlas University (OTHER)
First posted
Last updated

Brief Summary

Lipedema is a chronic adipose tissue disorder characterized by pain, tenderness, disproportionate fat accumulation, and impaired quality of life. Extracorporeal shock wave therapy (ESWT) has been proposed as a non-invasive treatment option that may improve pain and tissue characteristics in patients with lipedema. The aim of this prospective interventional study is to evaluate the effects of ESWT on pain intensity, quality of life, functional outcomes, and ultrasonographic findings in patients diagnosed with lipedema. Participants will receive a standardized ESWT protocol consisting of six treatment sessions over a two-week period. Clinical assessments and ultrasonographic examinations will be performed before and after treatment.

Frequently Asked Questions

What is Extracorporeal Shock Wave Therapy in Patients With Lipedema?

Extracorporeal Shock Wave Therapy in Patients With Lipedema is a clinical trial registered under NCT07683559. Current status: NOT_YET_RECRUITING.

What is the status of NCT07683559?

The current status of NCT07683559 (Extracorporeal Shock Wave Therapy in Patients With Lipedema) is: NOT_YET_RECRUITING.

When did Extracorporeal Shock Wave Therapy in Patients With Lipedema start?

Extracorporeal Shock Wave Therapy in Patients With Lipedema started on 2026-07-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.